Blog

Patients with loss of Y chromosome (LOY) had poorer prognosis when their bladders were removed, but somewhat paradoxically, better overall survival rates when they received immune checkpoint inhibitors

Photo from cedars-sinai.org

Jun 26, 2023, 19:13

Patients with loss of Y chromosome (LOY) had poorer prognosis when their bladders were removed, but somewhat paradoxically, better overall survival rates when they received immune checkpoint inhibitors

In a post by on Linkedin, it says, “It is terrific to see our study examining the loss of Y chromosome (LOY) and its effect on bladder cancer has been published in Nature. The loss of the Y chromosome has been observed in several cancer types, including many bladder cancers. The paper describes our studies of naturally occurring LOY mutant bladder cancer cells as well as those with targeted deletion of Y chromosome by CRISPR/Cas9. We found Y- tumors were more aggressive in immune competent hosts in a T cell-dependent manner. Our study also reviewed data on male patients with invasive bladder cancer who had their bladders removed and male patients who participated in an immune checkpoint inhibitor clinical trial. Patients with LOY had poorer prognosis when their bladders were removed, but somewhat paradoxically, better overall survival rates when they received immune checkpoint inhibitors.
These findings could also have implications for women since they experience more aggressive bladder cancer. The Y chromosome possesses a set of related genes, called paralogue genes, on the X chromosome, and these might play a role in both women and men.
We believe this study is the first published evidence that LOY cancer alters T cell function, allowing bladder cancer to elude the immune system and grow more aggressively. It provides insights into LOY biology and lays the groundwork for developing future biomarkers to improve cancer immunotherapy. I’d like to thank all of my fellow authors and everyone who helped with this research.”

For details: Click here

Source: